Tas13D inhibits growth of SMMC-7721 cell via suppression VEGF and EGF expression

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2009-2014

  He, Huai Zhen ^a   Wang, Nan ^a   Zhang, Jie ^a   Zheng, Lei ^a   Zhang, Yan Min ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chemotherapy; EGF; EGFR; SMMC 7721 cell; Tas13D; VEGF; VEGFR

Indexed keywords

ALKALOID; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; TASPINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ALKALOIDS; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872681149     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2009     Document Type: Article

References (27)

1. Carmeliet P (2005). Angiogenesis in life, disease and medicine. Nature, 438, 932-6.
2. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, et al (2006). Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer, 119, 2557-66.
3. Fayad W, Fryknas M, Brnjic S, et al (2009). Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. Plos One, 4, e7238.
4. Folkman J (1992). Introduction angiogenesis and cancer, Semin. Cancer Biol, 3, 47-8.
5. Han SW, Hwang PG, Chung DH, et al (2005). Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer, 113, 109-15.
6. Harichand-Herdt S, Ramalingam SS (2008). Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Semin Thorac Cardiovasc Surg, 20, 217-23.
7. Hirsch FR, Varella-Garcia M, Bunn PA, et al (2006). Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J Clin Oncol, 24, 5034-42.
8. Ishiwata I, Sudo T, Kiguchi K, et al (1999). Tumor angiogenesis factors produced by cancer cells. Hum Cell, 12, 37-46.
9. Kelly TR, Xie RL (1998). Total synthesis of taspine. J Org Chem, 63, 8045-8.
10. Kerbel RS (2000). Tumour angiogenesis: past, present and the near future. Carcinogenesis, 21, 505-15.
11. Kim ES, Khuri FR, Herbst RS (2001). Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol, 13, 506-13.
12. Klein S, Levitzki A (2009). Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol, 21, 185-93.
13. Li ZH, Zhao RJ, Wu XH, et al (2005). Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J, 19, 1979-85.
14. Liang GB, Zhang GP, Jin HM (2005). Influence of basic fibroblast growth factor on ECV304 cell migration. Chin J Pathophysiol, 21, 16-20.
15. Lin CM, Chang H, Chen YH, et al (2006). Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int Immunopharmacol, 6, 1690-8.
16. Martinez A (2006). A new family of angiogenic factors. Cancer Lett, 36, 157-63
17. Mou J, Fang H, Jing F, et al (2009). Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors. Bioorg Med Chem, 17, 4666-73.
18. Mu H, Ohashi R, Yan S, et al (2006). Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res, 70, 146-57.
19. Myoung H, Hong SP, Yun PY, et al (2003). Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci, 94, 215-20.
20. Naruse I, Ohmori T, Ao Y, et al (2002). Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer, 98, 310-5.
21. Perdue GP, Blomster RN, Blake DA, et al (1979). South American plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci, 68, 124-6.
22. Shimamura M, Hazato T, Ashino H, et al (2001).Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun, 289, 220-4.
23. Shyu KG, Tsai SC, Wang BW, et al (2004). Saikosaponin C induces endothelial cells growth, migration and capillary tube formation. Life Sci, 76, 813-26.
24. Sikander M, Malik S, Yadav D, et al (2011). Cytoprotective activity of a trans-chalcone against hydrogen peroxide induced toxicity in hepatocellular carcinoma (HepG2) cells. Asian Pac J Cancer P, 12, 2513-6.
25. Yu T, Hou FG, Liu MM, et al (2012). Norcantharidin anti-angiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer. Asian Pac J Cancer P, 13, 499-503.
26. Uchida C, Haas TL (2009). Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. Curr Pharm Des, 15, 411-21.
27. Yancopoulos GD, Davls S, Gale NW, et al (2000). Vascular-specific growth factors and blood vessel formation. Nature, 407, 242-8